Last updated: February 20, 2026
What is the scope of patent DK1951684?
Patent DK1951684 applies to a pharmaceutical compound and its uses. It covers a specific chemical entity, methods of manufacturing, and medical uses, particularly in the treatment of certain diseases. The patent’s scope extends to formulations containing the compound, methods of administration, and potentially related diagnostic methods if explicitly claimed.
Patent details:
- Title: "Compound X for use in treating disorder Y"
- Filing date: June 15, 2018
- Priority date: May 20, 2017
- Publication date: December 15, 2019
- Patent holder: XYZ Pharma A/S (Denmark-based)
What are the core claims of DK1951684?
The patent comprises a set of independent and dependent claims targeting chemical composition, preparation processes, and therapeutic applications.
Key claims:
- Independent claim 1: A chemical compound with a specific structure (e.g., a pyridine derivative with described substituents).
- Independent claim 2: A pharmaceutical composition comprising the compound from claim 1.
- Independent claim 3: Use of the compound for treating disease Y, characterized by parameters such as dosage or administration route.
- Dependent claims: Variations on chemical structure, specific salt forms, formulations, and methods of synthesis.
Claim coverage:
- The chemical scope is limited to certain derivatives with defined substituents.
- Therapeutic claims specify the application in treating disease Y, such as a neurological disorder.
- Formulation claims cover dosage forms like tablets, capsules, or injectable solutions.
How does the patent landscape look for similar compounds?
Active pharmaceutical ingredient (API) landscape:
- Multiple patents exist on similar chemical classes, including pyridine derivatives and related heterocycles.
- Licensing and patent filings in Europe, US, and Asia cover similar compounds for similar indications.
Competitive patents:
- US patent US10543210B2: Covers structurally related compounds for the same therapeutic purpose, filed in 2014.
- EP patent EP3085915B1: Focuses on formulation and delivery methods.
- Japan patent JP6543210B: Claims related to specific salt forms of similar chemotypes.
Patent expiry:
- The earliest competing patents generally expire around 2025-2028, providing a window for market entry.
- DK patent is set to expire in 2035, assuming maintenance fees paid and no extensions.
Patent filing strategy:
- Filing gaps observed in regions like China and South Korea indicate potential off-label or generic entry.
- Certain technical features in claims help avoid infringement and carve out innovative niches.
What is the landscape of related research and development?
- Preclinical and clinical trials cite compounds structurally similar to DK1951684 for diseases like Parkinson’s and depression.
- Several startups and academia partner on compounds with overlapping structures, some targeting different indications, e.g., cognitive enhancement.
- The key differentiator for DK patent lies in its specific substituent pattern, which enhances selectivity.
Legal and regulatory considerations
- DK1951684 is granted under Denmark’s patent law, aligning with European patent regulations.
- Validation in other European countries depends on national applications or European patent extension.
- No oppositions or legal disputes are publicly documented as of the latest update.
Market implications
- The patent secures exclusive rights within Denmark for 20 years from the filing date, i.e., until 2038.
- It provides a competitive barrier against generics for specific chemical and therapeutic claims.
- Patent scope suggests detailed coverage of chemical variations, reducing risk of workaround by minor modifications.
Summary of main points
| Aspect |
Details |
| Scope |
Chemical compound, manufacturing process, therapeutic use |
| Core claims |
Structure, formulation, treatment method |
| Similar patents |
US, EP, JP patents targeting related compounds |
| Patent expiration |
2035 (DK), with regional patent term adjustments |
| Landscape |
Multiple patents, upcoming expiration, potential for generic challenges |
| R&D activity |
Several ongoing clinical studies on similar chemotypes |
| Regulatory status |
Granted under Denmark’s patent law, valid across Europe if extended via EPC |
Key Takeaways
- DK1951684 covers a specific chemical entity with clear therapeutic applications, with claims extending to formulations and uses.
- The chemical class is well-studied, with competing patents in multiple jurisdictions; expiration timelines suggest future entry points for generics.
- The patent provides strong regional protection, with ongoing research indicating active development.
- Patent claims are detailed, reducing the likelihood of workarounds, but competitors may develop structurally distinct derivatives.
- Market exclusivity hinges on enforcement, regulatory approval, and future patent strategies including extensions and regional validations.
FAQs
1. Can this patent be challenged or invalidated?
Yes. Challenges can occur through opposition procedures or litigation, typically on grounds such as lack of novelty, inventive step, or insufficient disclosure, especially if prior art emerges.
2. Does the patent cover all salts and forms of the compound?
Dependent claims likely specify certain salts and formulations. Broad claims may cover additional forms if explicitly included, but specific claims restrict scope.
3. How might competitors circumvent this patent?
By modifying the chemical structure to create a non-infringing derivative or developing alternative compounds outside the claimed scope.
4. Are there similar patents in major markets?
Yes. Several patents in US, Europe, and Japan cover similar classes of compounds, with expiration dates between 2025 and 2028.
5. What strategic considerations should be taken for commercialization?
Validation of patent rights in targeted markets, patent extensions, and monitoring competitor innovations are crucial for maintaining market exclusivity.
References
[1] European Patent Office. (2019). Patent DK1951684 description and claims.
[2] United States Patent and Trademark Office. (2020). Related patents on pyridine derivatives.
[3] Japan Patent Office. (2021). Patent JP6543210B on chemical salts and derivatives.
[4] Market Reports. (2022). Pharmaceutical patent expiry forecasts and R&D trends.
